Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 21:48 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study...
September 12, 2024 16:56 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC

NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
October 16, 2023 14:40 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
February 17, 2022 17:42 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members

NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
January 24, 2022 15:52 ET | Source: BioAegis Therapeutics

BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022

NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
October 29, 2021 15:44 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
September 18, 2012 09:00 ET | Source: Sirona Biochem Corp.

Sirona Biochem Hires Ray Matthews & Associates

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 18, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), a biotechnology company specializing in carbohydrate...